Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome

British Journal of Haematology

Volumn 155, Issue 2, 2011, Pages 272-274

  Pellagatti, Andrea ^a   Cazzola, Mario ^b   Giagounidis, Aristoteles ^c   Perry, Janet ^a   Malcovati, Luca ^b   Della Porta, Matteo G ^b   Jädersten, Martin ^d   Killick, Sally ^e   Vyas, Paresh ^a   Hellström Lindberg, Eva ^d   Wainscoat, James S ^a   Boultwood, Jacqueline ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c ST JOHANNES HOSPITAL   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Del(5q); Myelodysplastic syndromes; NPM1

Indexed keywords

5Q- SYNDROME; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NPM1 GENE; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS;

ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HUMANS; NUCLEAR PROTEINS; SEQUENCE DELETION;

EID: 80053503649     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08672.x     Document Type: Letter

References (10)

1. Boultwood, J., Pellagatti, A., McKenzie, A.N. & Wainscoat, J.S. (2010) Advances in the 5q- syndrome. Blood, 116, 5803-5811.
2. Dicker, F., Haferlach, C., Sundermann, J., Wendland, N., Weiss, T., Kern, W., Haferlach, T. & Schnittger, S. (2010) Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia, 24, 1528-1532.
3. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254-266.
4. Fidler, C., Watkins, F., Bowen, D.T., Littlewood, T.J., Wainscoat, J.S. & Boultwood, J. (2004) NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica, 89, 865-866.
5. Grisendi, S., Bernardi, R., Rossi, M., Cheng, K., Khandker, L., Manova, K. & Pandolfi, P.P. (2005) Role of nucleophosmin in embryonic development and tumorigenesis. Nature, 437, 147-153.
6. Jadersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Gohring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellstrom-Lindberg, E. & Mufti, G.J. (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, In press.
7. La Starza, R., Matteucci, C., Gorello, P., Brandimarte, L., Pierini, V., Crescenzi, B., Nofrini, V., Rosati, R., Gottardi, E., Saglio, G., Santucci, A., Berchicci, L., Arcioni, F., Falini, B., Martelli, M.F., Sambani, C., Aventin, A. & Mecucci, C. (2010) NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. PLoS ONE, 5, e12855.
8. Pellagatti, A., Cazzola, M., Giagounidis, A., Perry, J., Malcovati, L., Della Porta, M.G., Jadersten, M., Killick, S., Verma, A., Norbury, C.J., Hellstrom-Lindberg, E., Wainscoat, J.S. & Boultwood, J. (2010) Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia, 24, 756-764.
9. Royer-Pokora, B., Trost, D., Muller, N., Hildebrandt, B., Germing, U. & Beier, M. (2006) Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia. Cancer Genetics and Cytogenetics, 167, 66-69.
10. Sportoletti, P., Grisendi, S., Majid, S.M., Cheng, K., Clohessy, J.G., Viale, A., Teruya-Feldstein, J. & Pandolfi, P.P. (2008) Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood, 111, 3859-3862.